Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:38 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC
NCT05400577 · Fox Chase Cancer Center · PHASE2 · withdrawn · last registry update 2023-07-17 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Grantor withdrew support due to slow accrual” | Open Targets' class: business administrative, insufficient enrollment, logistics resources | Registry record, Fox Chase Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KRAS in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-11Phase 3 first posted: Hoffmann-La Roche, Divarasib + Sotorasib (NCT06497556)
- 2024-03-29Also stopped (withdrawn): NYU Langone Health, Sotorasib + Ladarixin (NCT05815186)
- 2024-01-23Also stopped (withdrawn): M.D. Anderson Cancer Center, Durvalumab + Adagrasib (NCT05848843)
- 2023-10-18Also stopped (withdrawn): Criterium, Inc., AMG 510 + MVASI (NCT05180422)
- 2023-06-27Phase 3 first posted: Amgen, Sotorasib + Pembrolizumab (NCT05920356)
- 2023-05-10Results posted on the registry: Amgen, AMG 510 + Docetaxel (NCT04303780)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision